Usage Examples
- The QTPP fixed immediate release and a 30-minute dissolution target before formulation screening started.
- Every CQA in the control strategy traces back to a QTPP element, or it does not belong there.
- Changing the target release profile means reopening the QTPP and reassessing the whole CMC package.
What is Quality Target Product Profile (QTPP)?
Quality Target Product Profile is a prospective summary of the quality characteristics a drug product must achieve, covering dosage form, strength, delivery, release and stability, from which every critical quality attribute in the control strategy is derived.
The Quality Target Product Profile exists because quality cannot be tested into a product after the fact. ICH Q8(R2) states that quality should be built in by design, which is impossible unless the target is written down first. The QTPP is that written target, fixed before formulation and process choices quietly narrow what the product can become.
The QTPP covers intended clinical use, route of administration, dosage form and delivery system, dosage strengths, container closure system, therapeutic moiety release with the attributes affecting pharmacokinetics, and quality criteria such as sterility, purity, stability and drug release. The QTPP is written for the drug product. It informs drug substance CQAs under ICH Q11 but sets none itself, and it carries no acceptance criteria.
The QTPP is applied as the anchor of a traceable chain: QTPP element, potential drug product CQA, material attribute or process parameter, control strategy entry. Teams draft it at the start of formulation development and revise it as knowledge accumulates. Changing a QTPP element late forces reassessment of every CQA and control downstream, which is why the revision is expensive.
Not to be confused with
- Critical Quality Attribute (CQA)
- a CQA is a physical, chemical, biological or microbiological property that must sit within a limit, range or distribution. The QTPP is the target; CQAs are the measurable properties derived from it that prove the target is met.
- Product specification
- the specification is an element of the control strategy, applied at release with acceptance criteria attached. The QTPP is a development target with no acceptance criteria and no release decision riding on it.
- Analytical Target Profile (ATP)
- the ATP captures the measurement needs for QTPP-linked CQAs and drives the choice of analytical technology (ICH Q14, adopted 1 November 2023). The QTPP defines what the product must be; the ATP defines how well you must be able to measure it.
- Quality by Design (QbD)
- QbD is the systematic development approach that begins with predefined objectives. The QTPP is the document that states those objectives. Writing a QTPP is a step inside QbD, not evidence that QbD was applied.
ICH Q8(R2) prescribes no QTPP template. These are the obligations the guidelines actually place on it.
What you must do
- 1Document the QTPP as a prospective summary of the quality characteristics that ideally will be achieved to ensure the desired quality, taking into account safety and efficacy of the drug productICH Q8(R2) Part II §4
- 2Define the QTPP as it relates to quality, safety and efficacy, considering route of administration, dosage form, bioavailability, strength and stability, as a minimum element of pharmaceutical developmentICH Q8(R2) Part II §1
- 3Address the QTPP considerations that apply to the product: intended clinical use, delivery system, dosage strengths, container closure system, therapeutic moiety release, and drug product quality criteria for the intended marketed productICH Q8(R2) Part II §2.1
- 4Derive the potential drug product CQAs from the QTPP and prior knowledge, and use quality risk management to prioritise them for evaluationICH Q8(R2) Part II §2.2
- 5Use the QTPP together with the drug product CQAs to identify the potential CQAs of the drug substanceICH Q11 §3.1.1
Common mistakes
Writing the QTPP as a clinical wish list
indication, dosage form and a marketing aspiration, with no release, purity or stability target anyone can measure. A QTPP with no measurable characteristics cannot generate CQAs, so the CQA list ends up justified by convention rather than by the product, and the P.2 narrative has no load-bearing logic.
Letting the QTPP and the dossier drift apart
specifications, dissolution methods and process parameters keep moving through Phase 3 while the original QTPP sits untouched in the development file. The submission then argues from a target the rest of Module 3 no longer matches, which is a self-inflicted deficiency at review.
Skipping the drug substance link
deriving drug substance CQAs from supplier specifications instead of from the QTPP and drug product CQAs. ICH Q11 §3.1.1 runs the chain the other way, and breaking it means the 3.2.S sections cannot explain why any drug substance attribute is controlled at the level it is.
When This Matters
- The QTPP fixed immediate release and a 30-minute dissolution target before formulation screening started.
- Every CQA in the control strategy traces back to a QTPP element, or it does not belong there.
- Changing the target release profile means reopening the QTPP and reassessing the whole CMC package.
Frequently Asked Questions
A QTPP includes intended use in the clinical setting, route of administration, dosage form, delivery system, dosage strength, container closure system, therapeutic moiety release or delivery with the attributes affecting pharmacokinetics, and drug product quality criteria such as sterility, purity, stability and drug release. ICH Q8(R2) lists these as considerations, not a fixed template.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- CMC Workflows
Track ICH quality guidelines automatically and get alerts when changes impact your products
- Quality/QA Workflows
Track GxP regulation changes and enforcement trends
